Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;189(3):e86-e90.
doi: 10.1111/bjh.16499. Epub 2020 Feb 12.

Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

Ann S LaCasce  1 , R Gregory Bociek  2 , Ahmed Sawas  3 , Paolo Caimi  4 , Edward Agura  5 , Jeffrey Matous  6 , Stephen M Ansell  7 , Howland E Crosswell  8 , Miguel Islas-Ohlmayer  9 , Caroline Behler  10 , Eric Cheung  11 , Andres Forero-Torres  12 , Julie Vose  2 , Owen A O'Connor  3 , Neil Josephson  13 , Yinghui Wang  13 , Ranjana Advani  14
Affiliations

Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

Ann S LaCasce et al. Br J Haematol. 2020 May.
No abstract available

Keywords: Hodgkin lymphoma; autologous stem cell transplantation; bendamustine; brentuximab vedotin; first salvage therapy.

PubMed Disclaimer

References

    1. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M., Diehl, V.& International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586. https://doi.org/10.1200/JCO.2006.09.2403.
    1. LaCasce, A.S., Bociek, R.G., Sawas, A., Caimi, P., Agura, E., Matous, J., Ansell, S.M., Crosswell, H.E., Islas-Ohlmayer, M., Behler, C., Cheung, E., Forero-Torres, A., Vose, J., O'Connor, O.A., Josephson, N., Wang, Y. & Advani, R. (2018) Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood, 132, 40-48. https://doi.org/10.1182/blood-2017-11-815183.
    1. Martinez, C., Diaz-Lopez, A., Rodriguez-Calvillo, M., Garcia-Sanz, R., Terol, M.J., Perez-Ceballos, E., Jiménez, M.J., Cantalapiedra, A., Domingo-Domenech, E., Rodriguez, M.J., Sampol, A., Espeso, M., López, F.-J., Briones, J., García, J.F., Sureda, A. & Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma Bone Marrow Transplantation(GELTAMO) (2016) Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. British Journal of Haematology, 174, 859-867. https://doi.org/10.1111/bjh.14133.
    1. Moskowitz, C.H., Matasar, M.J., Zelenetz, A.D., Nimer, S.D., Gerecitano, J., Hamlin, P., Horwitz, S., Moskowitz, A.J., Noy, A., Palomba, L., Perales, M.-A., Portlock, C., Straus, D., Maragulia, J.C., Schoder, H. & Yahalom, J. (2012) Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood, 119, 1665-1670. https://doi.org/10.1182/blood-2011-10-388058.
    1. Moskowitz, C.H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M.H., Chen, A.I., Stiff, P., Gianni, A.M., Carella, A., Osmanov, D., Bachanova, V., Sweetenham, J., Sureda, A., Huebner, D., Sievers, E.L., Chi, A., Larsen, E.K., Hunder, N.N., Walewski, J.& AETHERA Study Group (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 385, 1853-1862. https://doi.org/10.1016/S0140-6736(15)60165-9.

Publication types

MeSH terms

Substances